"Trastuzumab" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A humanized monoclonal antibody against the ERBB-2 RECEPTOR (HER2). As an ANTINEOPLASTIC AGENT, it is used to treat BREAST CANCER where HER2 is overexpressed.
| Descriptor ID |
D000068878
|
| MeSH Number(s) |
D12.776.124.486.485.114.224.060.875 D12.776.124.790.651.114.224.060.875 D12.776.377.715.548.114.224.200.875
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Trastuzumab".
- Chemicals and Drugs [D]
- Amino Acids, Peptides, and Proteins [D12]
- Proteins [D12.776]
- Blood Proteins [D12.776.124]
- Immunoproteins [D12.776.124.486]
- Immunoglobulins [D12.776.124.486.485]
- Antibodies [D12.776.124.486.485.114]
- Antibodies, Monoclonal [D12.776.124.486.485.114.224]
- Antibodies, Monoclonal, Humanized [D12.776.124.486.485.114.224.060]
- Trastuzumab [D12.776.124.486.485.114.224.060.875]
- Serum Globulins [D12.776.124.790]
- Immunoglobulins [D12.776.124.790.651]
- Antibodies [D12.776.124.790.651.114]
- Antibodies, Monoclonal [D12.776.124.790.651.114.224]
- Antibodies, Monoclonal, Humanized [D12.776.124.790.651.114.224.060]
- Trastuzumab [D12.776.124.790.651.114.224.060.875]
- Globulins [D12.776.377]
- Serum Globulins [D12.776.377.715]
- Immunoglobulins [D12.776.377.715.548]
- Antibodies [D12.776.377.715.548.114]
- Antibodies, Monoclonal [D12.776.377.715.548.114.224]
- Antibodies, Monoclonal, Humanized [D12.776.377.715.548.114.224.200]
- Trastuzumab [D12.776.377.715.548.114.224.200.875]
Below are MeSH descriptors whose meaning is more specific than "Trastuzumab".
This graph shows the total number of publications written about "Trastuzumab" by people in this website by year, and whether "Trastuzumab" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2009 | 0 | 1 | 1 |
| 2015 | 1 | 0 | 1 |
| 2016 | 0 | 1 | 1 |
| 2017 | 14 | 6 | 20 |
| 2018 | 15 | 11 | 26 |
| 2019 | 5 | 5 | 10 |
| 2020 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Trastuzumab" by people in Profiles.
-
Impact of Dose Delays and Alternative Dosing Regimens on Pertuzumab Pharmacokinetics. J Clin Pharmacol. 2021 08; 61(8):1096-1105.
-
Whole blood stability evaluation of monoclonal antibody therapeutics using volumetric absorptive microsampling. Bioanalysis. 2021 Apr; 13(8):621-629.
-
Flexible care in breast cancer. ESMO Open. 2021 02; 6(1):100007.
-
Cardio-oncology care in the era of the coronavirus disease 2019 (COVID-19) pandemic: An International Cardio-Oncology Society (ICOS) statement. CA Cancer J Clin. 2020 11; 70(6):480-504.
-
Effect of Cardioprotective Drugs on Chemotherapy-Induced Heart Failure and New Risk Stratification. J Am Coll Cardiol. 2019 10 01; 74(13):1736.
-
Three-year follow-up from a phase 3 study of SB3 (a trastuzumab biosimilar) versus reference trastuzumab in the neoadjuvant setting for human epidermal growth factor receptor 2-positive breast cancer. Eur J Cancer. 2019 10; 120:1-9.
-
Predictive and prognostic value of stromal tumour-infiltrating lymphocytes before and after neoadjuvant therapy in triple negative and HER2-positive breast cancer. Eur J Cancer. 2019 09; 118:41-48.
-
The 41-gene classifier TRAR predicts response of HER2 positive breast cancer patients in the NeoALTTO study. Eur J Cancer. 2019 09; 118:1-9.
-
Treatment in real-life patients with HER2-positive metastatic breast cancer: What we learn from the KAMILLA trial? Eur J Cancer. 2019 08; 117:1-4.
-
When a metastatic breast cancer is mimicking a pancreatic cancer: case report and review of the literature. Acta Clin Belg. 2020 Aug; 75(4):301-307.